Revenue
No reported data
Trevi Therapeutics, Inc. (TRVI)
Price—Loading quote
Net income
2018
2019
2020
2021
2022
2023
2024
2025
Free cash flow
2018
2019
2020
2022
2023
2024
2025
Total cash / debt
CashTotal debt
2018
2019
2020
2021
2022
2023
2024
2025
Financial statements
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | |
|---|---|---|---|---|---|---|---|---|
| Research & development | $33.5M | $39.4M | $23.7M | $19.8M | $23.0M | $22.3M | $19.3M | $14.1M |
| Operating expenses | $49.3M | $51.5M | $33.9M | $29.9M | $32.5M | $32.5M | $26.6M | $18.4M |
| Operating income | −$49.3M | −$51.5M | −$33.9M | −$29.9M | −$32.5M | −$32.5M | −$26.6M | −$18.4M |
| EBITDAderived | −$49.2M | −$51.4M | −$33.8M | −$29.9M | — | — | — | — |
| Net income | −$42.8M | −$47.9M | −$29.1M | −$29.2M | −$33.9M | −$32.8M | −$26.1M | −$20.5M |
| Basic EPSper diluted share | -$0.32 | -$0.47 | -$0.29 | -$0.45 | -$1.49 | -$1.81 | -$2.28 | -$58.44 |
| Diluted EPSper diluted share | -$0.32 | -$0.47 | -$0.29 | -$0.45 | -$1.49 | -$1.81 | -$2.28 | -$58.44 |
Insider buys & sells
| Transaction | Insider | Type | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|
| Mar 25, 2025Form 4 | SCIASCIA THOMASChief Scientific Officer | SellCommon Stock | 2.6K | $6.60 | $17.4K | 221.4K |
| Mar 21, 2025Form 4 | GOOD JENNIFER LPresident & CEO | SellCommon Stock | 5.3K | $6.58 | $34.6K | 213.3K |
| Mar 10, 2025Form 4 · 10b5-1 | Simon FarrellChief Commercial Officer | SellCommon Stock | 4.3K | $7.15 | $31.1K | 76.9K |
| Mar 10, 2025Form 4 · 10b5-1 | Simon FarrellChief Commercial Officer | SellCommon Stock | 77.0K | $6.73 | $518.0K | 81.3K |
| Sep 9, 2024Form 4 | GOOD JENNIFER LPresident & CEO | SellCommon Stock | 1.8K | $3.04 | $5.6K | 213.3K |